Scrip’s Guide To The Month Ahead: July 2026
A quick round-up of upcoming pharma events, focusing on approvals and clinical trial results expected over the next four weeks.
Scrip - June 30, 2026

FDA Blocks Data From Third Chinese Lab
CCIC Huatongwei International Inspection falsified and copied data to create “biologically highly improbable” results, the regulator said.
Medtech Insight - June 30, 2026

India Initiates Anti-Dumping Probe Into Dialyzer Imports From China, Malaysia
India has launched a probe into dialyzer imports from China and Malaysia after Poly Medicure alleged dumped pricing is hurting domestic manufacturers. The investigation will assess pricing below normal value and resulting injury, with industry voices also pushing for a customs duty fix instead.
Medtech Insight - June 30, 2026

Abivax Back In Favor With Obefazimod Safety Update
Following a huge sell-off at the start of the month, the French firm’s stock has surged as investors regain confidence in the oral miR-124 enhancer’s benefit-risk profile as a treatment for ulcerative colitis.
Scrip - June 30, 2026

BIO 2026: Deals Are Surging Even As Chinese Competition And MFN Concerns Linger
Big pharma’s insatiable appetite for assets and dealmaking by small and mid-sized companies is ramping up in 2026. China continues to grow as a global R&D player, with many companies increasingly looking for best-in-class assets.
In Vivo - June 30, 2026

European Biotechs Unite To Warn Of Financing And Competition Gap
The European Life Sciences Coalition is speaking up for more co-ordinated action to improve funding, as competitive pressures from the US and China mount, and has a nine-point plan of its own.
Scrip - June 30, 2026

FDA Approves United Therapeutics’ LungFX For Centralized Lung Perfusion, On A Narrow Indication
The FDA approved the device indicated solely for centralized ex vivo lung perfusion, despite its pivotal study missing the survival goal and showing higher mortality than controls. The FDA limited use to lungs that couldn't otherwise be placed; rollout is set for 2027.
Medtech Insight - June 30, 2026

Stock Watch: Stubbornly Sticking To The Therapeutic Knitting
Companies that successfully harness a novel technology to develop new drugs are often able to milk that advantage for more than one blockbuster. But competition and commercial realities will eventually sour later efforts.
Scrip - June 30, 2026

Stada Acquires Orifarm VMS Brands To Emerge As Major Nordic CHC Player
Stada says its acquisition of Orifarm's dietary supplements portfolio will make the company one of the Nordics' top consumer health players.
Generics Bulletin - June 30, 2026

Samsung Bioepis Touts Phase III Results As Keytruda Competition Approaches
Samsung Bioepis has reported positive trial data for its SB27 proposed biosimilar to Keytruda (pembrolizumab). The firm has stuck to its position on conducting full trials for the candidate even as other developers streamline their biosimilar studies.
Generics Bulletin - June 30, 2026

‘We Have Plans For Rapid Expansion’ – How Newcomer Evumed Is Seeking To Compete In Europe
Evumed is a new name in the European off-patent market, backed by parent company Nanjing King-Friend and guided by the success of US sister company Meitheal. European commercial director and vice-president Matt Eddleston talks to Generics Bulletin about the firm’s growth plans.
Generics Bulletin - June 30, 2026

AI Opens Up Opportunities For Dietary Supplements, But Is Not Without Risk
IADSA's Simon Pettman and Cynthia Rousselot on how artificial intelligence unlocks new ways for dietary supplement brands to reach consumers, while simultaneously putting consumer trust in the sector at risk.
HBW Insight - June 30, 2026

China Early-Stage Trials Changing Global R&D Landscape For Rare Disease Drugs
Clinical results from China-only, investigator-initiated clinical trials and company-sponsored Phase I or II studies are now being integrated into the global development of rare disease drugs by US firms, although such data may still need to prove their worth with major regulators.
Scrip - June 30, 2026

Private Investment Key Part Of Japan’s $370bn Plan To Boost Pharma
A major new economic roadmap in Japan includes planned investments in novel drug development, biopharma manufacturing and infectious disease security, although foreign firms again highlight the need for pricing reforms to make the country a genuinely attractive market.
Scrip - June 30, 2026

After Digital Surgery Exit, Nehme Starts Regulatory Path For Morph’s Soft Robotics At Wellness
Jean Nehme, who sold Digital Surgery to Medtronic in 2020, has launched London start-up morph, building soft robotic cells — deformable materials that adapt in real time. His strategy: prove the platform in consumer wellness first, then build evidence for a regulated-device path.
HBW Insight - June 30, 2026

Testing Choices By Supplement Manufacturers Remain Common GMP Problems US FDA’s Finding
Small number among numerous requirements for manufacturing, packaging, holding and labeling set in 21 CFR Part 111are most common sources of problems FDA investigators continue to find since GMP rule effective for all manufacturers in 2010.
HBW Insight - June 30, 2026